Our in vivo experiments of allergic asthma mice demonstrated that, consistent with the Dex-treatment group, the EB-A treatment suppressed the typical features of allergic asthma, such as increased serum total IgE levels, lung inflammation, including inflammatory cells infiltration and cytokine production, airway hyperresponsiveness, airway remodeling, and lung injury. The gene discussed is IGHE; the disease is allergic asthma.